RN

Rahmat Nasir Khan

Active Director Director DIN 10050162
DIN 10050162 First appointment Feb 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2023
Shareholding value •••• Premium profile

About Rahmat Nasir Khan

Data last updated:

Rahmat Nasir Khan is a Director at Sorrir Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Sorrir Pharmaceuticals Private Limited reported revenue of ₹80.1 Lakh (FY 2025).

DIN 10050162
Primary Designation Director
Industry Pharma
First Appointment 19 Feb 2023
Oldest Company Age 3 yrs
Largest company Sorrir Pharmaceuticals Private Limited · ₹80.1 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Feb 20232023₹80.1 Lakh (FY 2025)Active

Board colleagues of Rahmat Nasir Khan

Directorship timeline

Open interactive timeline →
Sorrir Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rahmat Nasir Khan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahmat Nasir Khan

Rahmat Nasir Khan currently holds 1 directorship: Sorrir Pharmaceuticals Private Limited (Director, since 19 Feb 2023, revenue ₹80.1 Lakh (FY 2025)).

Rahmat Nasir Khan was first appointed on 19 Feb 2023 as Director at Sorrir Pharmaceuticals Private Limited.

The current boards of Rahmat Nasir Khan's companies include Shashikant Shivshankar Sharma (Sorrir Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available